NextCure and Simcere announced that their investigational antibody drug conjugate SIM0505, targeting Cadherin-6 with a topoisomerase 1 inhibitor payload, has been accepted for presentation at ASCO 2026. SIM0505 is currently in a Phase 1 trial focusing on advanced solid tumors, especially platinum-resistant ovarian cancer. This acceptance highlights progress in developing new cancer therapies and data readouts are expected in Q2 2026, potentially advancing treatment options for difficult-to-treat ovarian cancer cases. NextCure holds global rights outside China, Hong Kong, Macau, and Taiwan, which are retained by Simcere.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
